PTSD (Post-Traumatic Stress Disorder) is characterised by persistent re-experiencing of trauma, hyperarousal, avoidance, and negative mood/cognition changes rooted in dysregulation of fear memory consolidation, HPA axis function, and noradrenergic signalling. Conventional treatments — SSRIs, SNRIs, psychotherapy — leave many patients with significant residual symptoms. Research peptides that modulate GABA, BDNF, HPA axis, and dopamine pathways are of interest for PTSD presentations, with mechanistic rationale strongest for Selank, Semax, and BPC-157.
Research context only. The peptides discussed on WolveStack are research chemicals not approved for human use by the FDA. Nothing on this page constitutes medical advice. Consult a qualified healthcare professional before use.
The primary concern is interaction with existing PTSD medications. Selank's GABAergic effects may interact with prescribed benzodiazepines or GABA-modulating drugs. Semax's serotonergic component may interact with SSRIs or SNRIs at theoretical level.
Selank: Fear Memory and Anxiety Modulation
Selank's primary PTSD-relevant mechanism is its GABAergic modulation — acting on GABA-A receptors to reduce the tonic anxiety and hyperarousal that characterise PTSD. Unlike benzodiazepines, which also modulate GABA-A but cause dependence and memory impairment, Selank does not appear to impair memory consolidation (relevant for PTSD where therapeutic trauma memory processing is important) and has no documented addiction or withdrawal profile.
Selank also modulates enkephalin stability, which influences opioid receptor tone — relevant to the emotional numbing and anhedonia present in PTSD. Russian clinical research specifically examined Selank in anxious-depression states including stress-related anxiety disorders, showing benefits consistent with its mechanism in the PTSD-adjacent anxiety domain. For the hyperarousal, sleep disruption, and anxiety components of PTSD, Selank's profile is well-aligned.
Semax: Trauma Memory and Neuroplasticity
BDNF is intimately involved in fear memory consolidation and extinction — the process by which the brain "updates" fear associations. Reduced hippocampal BDNF is associated with impaired fear extinction, meaning fear memories persist without update even when safety has been re-established. This is a key neurobiological feature of treatment-resistant PTSD. Semax's potent BDNF upregulation in hippocampal and cortical structures provides a mechanism for supporting fear extinction — potentially improving responsiveness to exposure-based psychotherapy by restoring the neuroplasticity needed for new safety learning to compete with existing trauma memories.
This effect is not established in formal PTSD clinical trials, but the mechanistic connection between BDNF, fear extinction, and Semax's pharmacology is one of the more compelling research hypotheses in the peptide-PTSD space. Several researchers have proposed combining Semax with exposure therapy protocols, paralleling MDMA-assisted and ketamine-based approaches that also target neuroplasticity windows during trauma processing.
BPC-157: HPA Axis and Dopamine System
The HPA axis (hypothalamic-pituitary-adrenal axis) is chronically dysregulated in PTSD — typically in the direction of low cortisol with elevated CRF (corticotropin-releasing factor) and exaggerated cortisol response to stressors, reflecting a sensitised stress response system. BPC-157's documented effects on HPA axis normalisation in chronic stress models are directly relevant here: it reduces ACTH-stimulated corticosterone responses and attenuates the dopaminergic blunting that accompanies chronic stress exposure.
The dopamine system involvement is particularly important for PTSD's motivational and hedonic deficits — the anhedonia and emotional blunting that persist after hyperarousal treatment. BPC-157's dopaminergic restoration effects (protecting D1 and D2 receptor sensitivity against stress-induced changes) address a mechanistic gap that GABAergic and serotonergic treatments don't cover.
How Does Peptides for Work?
| Peptide | Dose | Route | Frequency | Notes |
|---|---|---|---|---|
| Selank | 250–500 mcg | Intranasal | GABAergic / anxiety / sleep | Hyperarousal, fear, sleep disruption |
| Semax | 200–600 mcg | Intranasal | BDNF / fear extinction / dopamine | Emotional numbing, cognitive symptoms |
| BPC-157 | 250–500 mcg | SubQ or oral | HPA axis / dopamine restoration | Stress sensitisation, anhedonia |
| DSIP | 100–300 mcg | SubQ | Cortisol normalisation / sleep architecture | HPA dysregulation, insomnia |
Also Available at Apollo Peptide Sciences
Apollo Peptide Sciences carries independently tested research-grade compounds. Products ship from the USA with published purity certificates.
For research purposes only. Affiliate disclosure: WolveStack earns a commission on qualifying purchases at no additional cost to you.
Frequently Asked Questions
No — peptides should be understood as potential adjuncts to psychological treatment, not replacements. PTSD has a complex psychological dimension that requires therapeutic processing that no pharmacological compound, including peptides, can substitute for. The most compelling hypothesis is that peptides like Semax (via BDNF) and Selank (via anxiety reduction) could improve responsiveness to therapy by optimising the neurobiological environment for trauma memory processing.
The primary concern is interaction with existing PTSD medications. Selank's GABAergic effects may interact with prescribed benzodiazepines or GABA-modulating drugs. Semax's serotonergic component may interact with SSRIs or SNRIs at theoretical level. BPC-157 is mechanistically less likely to interact with psychiatric medications. Disclosing any research peptide use to a treating physician is advisable, particularly in a psychiatric medication context.
DSIP has the strongest mechanistic basis for sleep-specific PTSD symptoms (nightmares, sleep disruption) through its effects on slow-wave sleep and cortisol normalisation. Selank's GABAergic and sleep-improving effects also contribute. These are complementary: DSIP for sleep architecture restoration, Selank for hyperarousal-related sleep initiation difficulties. Prazosin (alpha-1 blocker, reduces noradrenergic hyperarousal during sleep) is the standard clinical approach for PTSD nightmares; peptides would be adjuncts rather than replacements.